MedTrace Logo

Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)

NCT04937907 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-02

No results posted yet for this study

Summary

This Phase 2 randomized controlled trial will study the safety, tolerability, and efficacy of Hydroxychloroquine in qualified patients with Alport syndrome. The trial will be open-label, randomized, controlled and will enroll up to 50 patients.

Conditions

  • Alport Syndrome, X-Linked

Interventions

DRUG

Hydroxychloroquine Sulfate 100 milligram (mg) Tab

Patients administered HCQ by oral at a dose of 6.5mg per kilogram twice a day at least 6 months.

DRUG

Benazepril hydrochloride 10 milligram (mg) Tab

Patients administered Benazepril by oral at a dose of 5mg or 10mg once a day at least 6 months.

Sponsors & Collaborators

  • Shanghai Children's Hospital

    lead OTHER

Principal Investigators

  • Wen-yan Huang, PhD · Shanghai Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-08
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04937907 on ClinicalTrials.gov